Explore our comprehensive portfolio that addresses the complete care continuum for many of the world’s most threatening diseases. 

Siemens Healthineers Shape Spotlight

Explore Shape
Industry trends

Insights

Discover the stories of pioneers pushing the boundaries of what’s possible in healthcare to help improve people’s lives around the world.

Patient-centered innovation has been and always will be at the core of our company. Dive deeper into our fascinating technologies.

We pioneer breakthroughs in healthcare. For everyone. Everywhere. Sustainably. Learn more about our purpose, our innovation leadership, our culture, and our strategy.

  1. Home

  2. Press center
  3. Press releases
  4. Siemens Healthineers ends 2026 fiscal year with strong fourth quarter
New corporate headquarters in Erlangen
Press release

Siemens Healthineers ends 2026 fiscal year with strong fourth quarter

Siemens Healthineers AG today announces its results for the fourth quarter of fiscal year 2026 ended September 30, 2026, and the full fiscal year 2026.
Published on November 5, 2026

Fiscal Year 2026

  • Very good equipment book-to-bill ratio of 1.14
  • Comparable revenue growth of 4.0%
  • Adjusted EBIT margin of 16.2%; adjusted EBIT of around €3.8 billion
  • Adjusted basic earnings per share of €2.42
  • Free cash flow of around €2.4 billion
  • Proposed dividend of €1.00 per share (prior year: €1.00)

Q4 Fiscal Year 2026

  • Very good equipment book-to-bill ratio of 1.15
  • Strong comparable revenue growth of 5.9%
  • Adjusted EBIT margin of 15.9%
  • Imaging comparable revenue growth of 10.0%; adjusted EBIT margin of 21.9%
  • Precision Therapy comparable revenue growth of 4.8%; adjusted EBIT margin of 13.8%
  • Diagnostics comparable revenue decline of 4.2%; adjusted EBIT margin of 5.4%
  • Adjusted basic earnings per share of €0.69
  • Free cash flow of €703 million

Outlook for Fiscal Year 2027

For fiscal year 2027, we expect comparable revenue growth between 4.0% and 5.0% over fiscal year 2026. For adjusted basic earnings per share, we expect a range of between €2.20 and €2.40.

Bernd Montag, CEO of Siemens Healthineers AG:

”We closed out the last fiscal year with a strong fourth quarter. In this new fiscal year, we are shaping our next phase with a different shareholder structure, and enhancing corporate clarity. Our brand evolution and name will reflect who we are: Healthineers. We are sharpening our portfolio – further strengthening our core, while positioning our Diagnostics business for a successful future and initiating the carve-out process. Our ‘Elevating Health Globally’ strategy is on track, further expanding our innovation leadership with a clear focus on the most prevalent non-communicable diseases, for the benefit of 8 billion people.“

Download Quarterly Statement(pdf, 281.24 KB)

Siemens Healthineers 2027

Siemens Healthineers (DAX: SHL) pioneers breakthroughs in healthcare. For everyone. Everywhere. Sustainably. A leader in healthcare technology, Siemens Healthineers aims to elevate health globally by striving to overcome the most threatening diseases – cancer, stroke, cardiovascular and neurodegenerative diseases – and to improve access to care for underserved communities worldwide. We are active in imaging, cancer care, minimally invasive therapies, in-vitro diagnostics and radiopharmaceuticals, backed by healthcare AI solutions that enable personalized care at scale. Siemens Healthineers does business in more than 180 countries with direct representation in more than 70, partnering with healthcare providers to address their most pressing challenges. In the fiscal year ending September 30, 2026, Siemens Healthineers had around 75,000 employees worldwide and generated revenue of around €23.6 billion. Further information is available at siemens-healthineers.com.